Protara Therapeutics (NASDAQ:TARA) Earns “Buy” Rating from HC Wainwright

Protara Therapeutics (NASDAQ:TARA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $23.00 price objective on the stock.

Separately, Oppenheimer dropped their price target on shares of Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th.

Protara Therapeutics Trading Down 4.3 %

TARA stock opened at $2.47 on Thursday. Protara Therapeutics has a 1-year low of $1.04 and a 1-year high of $5.24. The business’s 50-day moving average price is $2.03 and its two-hundred day moving average price is $2.29. The firm has a market cap of $50.96 million, a PE ratio of -0.91 and a beta of 1.77.

Insider Activity

In other Protara Therapeutics news, major shareholder Opaleye Management Inc. sold 32,600 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $1.71, for a total transaction of $55,746.00. Following the sale, the insider now owns 51,500 shares of the company’s stock, valued at approximately $88,065. This represents a 38.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Protara Therapeutics during the third quarter valued at about $60,000. Oppenheimer & Co. Inc. raised its stake in shares of Protara Therapeutics by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after buying an additional 51,944 shares during the period. CVI Holdings LLC bought a new position in Protara Therapeutics in the 2nd quarter worth approximately $630,000. Armistice Capital LLC purchased a new stake in Protara Therapeutics during the 2nd quarter worth about $1,082,000. Finally, Marshall Wace LLP bought a new position in Protara Therapeutics in the 2nd quarter worth about $161,000. 38.13% of the stock is owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.